| Citation: |
MO Yanxiu, YAO Feihong, LIU Juntong, HU Ziang, LI Mulan. Effects of SP600125 on Proliferation and Invasion of Human Cervical Cancer HeLa Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(4): 304-313. DOI: 10.3971/j.issn.1000-8578.2022.21.0807
|
To investigate the effect of SP600125 on the proliferation, cell cycle, apoptosis and invasion of human cervical cancer HeLa cells.
CCK-8 method was used to detect the proliferation of HeLa cells treated with different concentrations of SP600125 at different time points. The 20 μmol/L of SP600125 was determined for subsequent experiments. Cell proliferation ability was detected using plate clone formation assay; nuclear morphology was observed by DAPI staining; cell cycle and apoptosis were measured by flow cytometry; cell migration and invasion were detected by cell scratch and Transwell methods; the mRNA and protein levels of p53, Mad2L1 and CDC20 were measured by qRT-PCR and Western blot after SP600125 treatment at different time points.
Compared with control group (0.1%DMSO), cells proliferative activity were reduced by 10, 20, 30, 40 and 50 μmol/L SP600125 treatment for 24h. Compared with control group, the rate of apoptosis was significantly increased in SP600125 treatment groups, and the cell proportion in G2/M phase increased (P < 0.001), while the cell proportion in G0/G1 phases cells was reduced after SP600125 treatment for 24h and 48h (P < 0.001), and the clonal number, migration and invasion ability of HeLa cells also decreased significantly (P < 0.001). qRT-PCR and Western blot results showed a significant decrease in Mad2L1 mRNA and protein expression (P < 0.05) and a significant increase in p53 and CDC20 mRNA and protein expression (P < 0.01).
SP600125 can induce cell cycle arrest of cervical cancer HeLa cells in G2/M phase by upregulating p53 and CDC20 and downregulating Mad2L1 expression, and promote cell apoptosis to inhibit cell proliferation, migration and invasion.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Lindeque G. A perspective on cervical cancer prevention and screening in Africa[J]. Int J Gynecol Obstet, 2021, 152(1): 133-134. doi: 10.1002/ijgo.13476
|
| [2] |
Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint[J]. Nat Rev Cancer, 2005, 5(10): 773-785. doi: 10.1038/nrc1714
|
| [3] |
Wu Q, Wu W, Jacevic V, et al. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer[J]. J Enzyme Inhib Med Chem, 2020, 35(1): 574-583. doi: 10.1080/14756366.2020.1720013
|
| [4] |
Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase[J]. Proc Natl Acad Sci U S A, 2001, 98(24): 13681-13686. doi: 10.1073/pnas.251194298
|
| [5] |
Zhou Y, Jiang M, Wang M, et al. Effect of SP600125 on proliferation of embryonic stem cell[J]. Am J Mol Biol, 2013, 3(2): 67-71. doi: 10.4236/ajmb.2013.32009
|
| [6] |
莫艳秀. SP600125诱导鱼类细胞多倍化的分子机制研究[D]. 长沙: 湖南师范大学, 2019.
Mo YX. Molecular mechanism of SP600125-induced cell polyploidization in fish[D]. Changsha: Hunan Normal University, 2019.
|
| [7] |
Kim JH, Chae M, Choi AR, et al. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition[J]. Eur J Pharmacol, 2014, 723: 141-147. doi: 10.1016/j.ejphar.2013.11.026
|
| [8] |
Xu W, Mo Y, He Y, et al. A New Method for Chromosomes Preparation by ATP-Competitive Inhibitor SP600125 via Enhancement of Endomitosis in Fish[J]. Front Bioeng Biotechnol, 2021, 8: 606496. doi: 10.3389/fbioe.2020.606496
|
| [9] |
Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease[J]. Nat Rev Cancer, 2010, 10(2): 102-115. doi: 10.1038/nrc2781
|
| [10] |
Sarkar S, Sahoo PK, Mahata S, et al. Mitotic checkpoint defects: en route to cancer and drug resistance[J]. Chromosome Res, 2021, 29(2): 131-144. doi: 10.1007/s10577-020-09646-x
|
| [11] |
Arbyn M, Gultekin M, Morice P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem[J]. Int J Cancer, 2021, 148(2): 277-284. doi: 10.1002/ijc.33189
|
| [12] |
Lee HJ, Wang CJ, Kuo HC, et al. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK[J]. Toxicol Appl Pharmacol, 2005, 203(2): 124-131. doi: 10.1016/j.taap.2004.08.004
|
| [13] |
Lu Z, Chen H, Zheng XM, et al. Experimental study on the apoptosis of cervical cancer Hela cells induced by juglone through c-Jun N-terminal kinase/c-Jun pathway[J]. Asian Pac J Trop Med, 2017, 10(6): 572-575. doi: 10.1016/j.apjtm.2017.06.005
|
| [14] |
高天. 单独或联合应用柴胡皂苷D和JNK抑制剂SP600125对人骨肉瘤U-2OS细胞的影响[D]. 南昌: 南昌大学, 2019.
Gao T. Use of Saikosaponin D and JNK inhibitor SP6oo125, alone or in combination, inhibits malignant properties of human osteosarcoma U-2OS cells[D]. Nanchang: Nanchang University, 2019.
|
| [15] |
Qin X, Zheng S, Liu T, et al. Roles of phosphorylated JNK in Esophageal Squamous Cell Calcinoma of Kazakh Ethnic[J]. Mol Carcinog, 2014, 53(7): 526-536. doi: 10.1002/mc.22004
|
| [16] |
周燕红, 何小飞, 高卉, 等. JNK信号通路在大肠癌侵袭和转移中的作用及机制[J]. 世界华人消化杂志, 2009, 17(21): 2142-2146. doi: 10.3969/j.issn.1009-3079.2009.21.005
Zhou YH, He XF, Gao H, et al. Mechanisms underlying the role of JNK signaling pathway in the invasion and metastasis of colon cancer cells[J]. Shijie Hua Ren Xiao Hua Za Zhi, 2009, 17(21): 2142-2146. doi: 10.3969/j.issn.1009-3079.2009.21.005
|
| [17] |
许雪梅. JNK抑制剂SP600125对人舌鳞癌Tca8113细胞增殖、迁移的影响[D]. 延吉: 延边大学, 2017.
Xu XM. Effects of JNK inhibitor SP600125 on proliferation and migration of Human Tongue Squamous Carcinoma Tca8113 cells[D]. Yanji: Yanbian University, 2017.
|
| [18] |
Jemaà M, Vitale I, Kepp O, et al. Selective killing of p53-deficient cancer cells by SP600125[J]. EMBO Mol Med, 2012, 4(6): 500-514. doi: 10.1002/emmm.201200228
|
| [19] |
陈新艳. 丝裂原活化蛋白激酶抑制剂逆转卵巢癌细胞奥拉帕尼耐药性的试验研究[D]. 济南: 山东大学, 2019.
Chen XY. Mitogen-activated protein kinase inhibitors increase sensitivity of olaparib-resistant ovarian cancer[D]. Ji'nan: Shandong University, 2019.
|
| [20] |
Mili D, Abid K, Rjiba I, et al. Effect of SP600125 on the mitotic spindle in HeLa Cells, leading to mitotic arrest, endoreduplication and apoptosis[J]. Mol Cytogenet, 2016, 9: 86. doi: 10.1186/s13039-016-0296-y
|
| [21] |
Agarwal ML, Agarwal A, Taylor WR, et al. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts[J]. Proc Natl Acad Sci U S A, 1995, 92(18): 8493-8497. doi: 10.1073/pnas.92.18.8493
|
| [22] |
Aylon Y, Oren M. p53: guardian of ploidy[J]. Mol Oncol, 2011, 5(4): 315-323. doi: 10.1016/j.molonc.2011.07.007
|
| [23] |
Sun C, Li M, Feng Y, et al. MDM2-P53 signaling pathway-mediated upregulation of CDC20 promotes progression of human diffuse large B-cell lymphoma[J]. Onco Targets Ther, 2020, 13: 10475-10487. doi: 10.2147/OTT.S253758
|
| [24] |
Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time[J]. Nat Rev Mol Cell Biol, 2007, 8(5): 379-393.
|
| [25] |
Barbosa J, Nascimento AV, Faria J, et al. The spindle assembly checkpoint: perspectives in tumorigenesis and cancer therapy[J]. Front Biol, 2011, 6(2): 147-155. doi: 10.1007/s11515-011-1122-x
|
| [26] |
Furlong F, Fitzpatrick P, O'Toole S, et al. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer[J]. J Pathol, 2012, 226(5): 746-755. doi: 10.1002/path.3035
|
| [27] |
Takahashi T, Haruki N, Nomoto S, et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers[J]. Oncogene, 1999, 18(30): 4295-4300. doi: 10.1038/sj.onc.1202807
|
| [28] |
Wang L, Wang J, Jin Y, et al. Downregulation of Mad2 and BubR1 increase the malignant potential and nocodazole resistance by compromising spindle assembly checkpoint signaling pathway in cervical carcinogenesis[J]. J Obstet Gynaecol Res, 2019, 45(12): 2407-2418. doi: 10.1111/jog.14120
|
| [29] |
Clijsters L, Ogink J, Wolthuis R. The spindle checkpoint, APC/C(Cdc20), and APC/C(Cdh1) play distinct roles in connecting mitosis to S phase[J]. J Cell Biol, 2013, 201(7): 1013-1026. doi: 10.1083/jcb.201211019
|
| [30] |
Wang S, Chen B, Zhu Z, et al. CDC20 overexpression leads to poor prognosis in solid tumors: a system review and meta-analysis[J]. Medicine(Baltimore), 2018, 97(52): e13832.
|
| [31] |
齐晓光, 祁春艳, 秦博宇, 等. 基于TCGA数据库筛选和鉴定肺腺癌免疫治疗临床获益关键基因[J]. 肿瘤防治研究, 2020, 47(11): 839-845. doi: 10.3971/j.issn.1000-8578.2020.20.0115
Qi XG, Qi CY, Qin BY, et al. Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database[J]. Zhong Liu Fang Zhi Yan Jiu, 2020, 47(11): 839-845. doi: 10.3971/j.issn.1000-8578.2020.20.0115
|
| [32] |
Guo W, Zhong K, Wei H, et al. Long non-coding RNA SPRY4-IT1 promotes cell proliferation and invasion by regulation of Cdc20 in pancreatic cancer cells[J]. PLoS One, 2018, 13(2): e0193483. doi: 10.1371/journal.pone.0193483
|
| [33] |
Cheng S, Castillo V, Sliva D. CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity[J]. Int J Oncol, 2019, 54(6): 2250-2256.
|
| [34] |
Supsavhad W, Hassan BB, Simmons JK, et al. Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases[J]. Vet Sci, 2021, 8(8): 153. doi: 10.3390/vetsci8080153
|
| [35] |
Xiong C, Wang Z, Wang G, et al. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma[J]. Invest New Drugs, 2021, 39(5): 1439-1453. doi: 10.1007/s10637-021-01126-1
|
| [36] |
Zhang Q, Huang H, Liu A, et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of beta-catenin in cancer stem-like cells[J]. EBio Medicine, 2019, 42: 397-407.
|
Figures(9) / Tables(1)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: